Intellective Bio has an experienced recombinant protein R&D technical team with experience in R&D, process development and declaration of several marketed antibody drugs. With the unique platform of independent expression system, independent medium platform and high-throughput detection and analysis platform, Intellective Bio rapidly provides high-quality protein-related technical services and protein products for domestic and foreign pharmaceutical companies and research institutes.

Intellective Bio has a full set of large molecule developability research technologies, which can provide services such as protein physical and chemical characterization, post-translational modification analysis, stability assessment, etc. By evaluating the developability and stability of candidate molecules, we can help researchers to narrow down the scope of screening and reduce the risk of failure in drug discovery.

Intellective Bio has a variety of recombinant protein expression platforms, such as mammalian cells, prokaryotic, yeast, etc., which can quickly provide customers with high-quality, low-cost active recombinant proteins. We have completed 200+ recombinant proteins preparation services, including multiple types of antibodies (mono-antibodies, bi-antibodies, multi-antibodies, etc.), antigens, enzymes and other proteins.

With industry-leading antibody engineering and recombinant antibody production platforms, Intellective Bio can provide partners with high-quality antibody humanization and affinity maturation integration services. Based on the principle of CDR transplantation and revert mutation, combined with bioinformatics and structural biology tools to assist design and optimization, the immunogenicity of antibody proteins can be attenuated quickly and effectively, while maintaining high affinity, activity, stability and yield.